Surgical treatment of liver metastases☆
Abstract
Approximately 50% to 60% of patients with colorectal cancer will develop hepatic metastases during the course of their illness, with 20% to 30% of patients having liver metastases at time of diagnosis. In nearly a quarter of these patients the liver is the only site of disease. Surgical resection of isolated hepatic metastases has been associated with a 27% to 37% 5-year survival and confers a survival advantage compared to patients not undergoing resection. Thorough preoperative and intraoperative evaluation is necessary to select appropriate surgical candidates who may benefit from resection. This article examines criteria useful in patient selection, and also reviews the management of recurrent hepatic metastases and the role of repeat hepatic resection. Semin Oncol 29:107-118. Copyright 2002, Elsevier Science (USA). All rights reserved.
To access this article, please choose from the options below
☆ Address reprint requests to Elin R. Sigurdson, MD, PhD, Department of Surgical Oncology, Fox Chase Cancer Center, 7701 Burholme Ave, Philadelphia, PA 19111.
PII: S0093-7754(02)50131-7
doi:10.1053/sonc.2002.31676
© 2002 Elsevier Science (USA). All rights reserved.
